ArticleAdvances in therapy2026
Real-World Treatment Patterns in Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan: A Retrospective Health Administrative Data Analysis.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSince 2020, several androgen receptor signaling inhibitors (ARSIs) have been approved for use among patients with metastatic castration-sensitive prostate cancer (mCSPC) in Japan. To evaluate how these approvals may have changed the mCSPC treatment landscape in Japan, we analyzed treatment patterns and time to treatment discontinuation (TTD) since 2020 in patients with mCSPC.
methodsThis retrospective cohort study utilized data from the Medical Data Vision health administrative database between May 2020 and March 2024. Study endpoints were patient characteristics at baseline, first-line, and subsequent-line treatment patterns; TTD of first-line therapies; and TTD of first-line ARSIs. Patient characteristics were analyzed descriptively. Hazard ratios (HRs) for TTD between treatment classes were calculated using an inverse probability of treatment weight-adjusted Cox proportional hazards model.
resultsOverall, 8830 patients with mCSPC were identified. Treatment with androgen-deprivation therapy (ADT) plus ARSI increased during follow-up, while treatment with ADT plus nonsteroidal antiandrogens (NSAAs) decreased. Transition from first- to second-line therapy occurred in approximately 32% of patients. Patients who received first-line ADT plus ARSI had a lower risk of treatment discontinuation compared with patients who received first-line ADT alone (adjusted HR 0.62, 95% CI 0.59-0.65) or ADT plus NSAA (adjusted HR 0.50, 95% CI 0.48-0.52). Among ARSIs, ADT plus enzalutamide had the longest median TTD.
conclusionUse of ARSIs for mCSPC is increasing, but ADT alone and ADT plus NSAA are still frequently used. The longer treatment duration among patients who received ARSIs indicates that treatment intensification with ARSIs is vital for mCSPC disease control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.